|
WO2013006745A2
|
|
High throughput genome-wide translocation sequencing
|
|
WO2012166611A2
|
|
Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
|
|
WO2012122015A2
|
|
Selective inhibitors of tumor-initiating cells
|
|
AU2012200909A1
|
|
Natural lgM antibodies and inhibitors thereof
|
|
WO2012078637A2
|
|
Composition and method for oligonucleotide delivery
|
|
WO2012048316A2
|
|
Regulators of nfat and/or store-operated calcium entry
|
|
EP2558571A2
|
|
Sustained polypeptide expression from synthetic, modified rnas and uses thereof
|
|
US2013040845A1
|
|
Method for screening receptors/ligands interactions
|
|
US8048864B1
|
|
Regulators of NFAT and/or store-operated calcium entry
|
|
WO2010037001A2
|
|
Selective oxidation of 5-methylcytosine by tet-family proteins
|
|
WO2010033818A2
|
|
Mirna targets
|
|
US2009317375A1
|
|
Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
|
|
US2010285002A1
|
|
Treatment or prevention of inflammation by targeting cyclin d1
|
|
US2011177155A1
|
|
Methods of delivery of agents to leukocytes and endothelial cells
|
|
EP2244700A1
|
|
Stromal interacting molecule knockout mouse and uses thereof
|
|
WO2008092081A2
|
|
Targeted delivery of sirna
|
|
WO2008054544A2
|
|
Method for delivery across the blood brain barrier
|
|
US2010008937A1
|
|
Targeted delivery to leukocytes using non-protein carriers
|
|
US2009232730A1
|
|
Method of producing immunoliposomes and compositions thereof
|
|
US2008311130A1
|
|
Integrin alpha L I domain mutants with increased binding affinity
|
